ARGON MEDICAL, Cook Group and C. R. Bard, Inc are Dominating the Market for Europe Breast Lesion Localization Methods Market in 2017

ARGON MEDICAL :

ARGON MEDICAL, incepted in 1972 and headquartered at Texas, U.S. The company is engaged in the production of stainless steel guidewires for critical care procedures, interventional cardiology interventional radiology, and vascular surgery. It is one of the pioneered companies in thrombus management, dialysis, vascular tools, drainage catheters and bone and soft tissue biopsy needles.

Access Full Report at https://databridgemarketresearch.com/reports/europe-breast-lesion-localization-methods-market/

It has 800 employees globally. It has its global networks through direct sales representatives and distributors in the United States and internationally. It operates as a subsidiary of ACI Medical Devices, Inc.

Cook Group:

Founded in 1963 and headquarter at Bloomington, Indiana, Cook Group is a privately held company which is focusing in the manufacturing of medical devices. The company operates through three main divisions, namely, Cook Services Cook Medical, and Cook Properties. These three segments are operated by various subsidiaries present globally. The first products of company included catheters, needles, and wire guides.

Cook Medical offers more than 16,000 products across 13 hospital service lines, and provides its services to over 135 countries.

R. Bard, Inc.:

Founded in 1907 and headquartered at Murray Hill, New Jersey, U.S. C. R. Bard, Inc. is engaged in the development, manufacturing and marketing of medical technologies. The company operates through four business segments: vascular, urology, oncology and surgical specialties. The vascular segment offers a wide range of products for endovascular and grafts includes biopsy devices, peripheral angioplasty catheters, drug-coated PTA balloons, vena cava filters, peripheral vascular stents and stent grafts, dialysis access grafts and peripheral vascular grafts. The urology segment of the company offers various products pertaining to basic drainage, continence, urological specialty, catheter stabilization, targeted temperature and management’s products. The oncology segment of the company offers various devices including implantable ports, peripherally inserted central catheters (PICCs) and vascular access ultrasounds. The key products included in the surgical specialties are soft tissue repair, performance irrigation and bio-surgical products.

  1. R. Bard, Inc. has companies operating across the North America, Europe, Middle East, and Asia-Pacific. Some of its subsidiaries include Bard Access System Inc. (U.S.), Bard Medical Division (U.S.), Davol Inc. (U.S.), Bard Peripheral Vascular, Inc. (U.S.), Bard Limited (U.K.), Bard Biopsy System (U.S.), Bard LAPAC (U.S.), Liberator Medical Supply, Inc. (U.S.), C. R. Bard GmbH (UAE) and many more subsidiaries across the globe.

Market Developments:

  • In November 2017, Cianna Medical, Inc. has received FDA approval for the SAVI SCOUT for long term implant, which is an integral part of the SCOUT system for wire-free breast tumor localization.
  • In November 2016, Cianna Medical, Inc. has received FDA 510 (k) clearance for the SAVI SCOUT radar localization system, which allows reflector to be placed at the lumpectomy site up to 30 days prior to surgical removal.